A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2002
11/07/2002	CA2601222A1 Once-a-day oxycodone formulations
11/07/2002	CA2594883A1 Pharmaceutically active uridine esters
11/07/2002	CA2450018A1 Crystal of 6-[4-(4-pyridylamino)phenyl]-4, 5-dihydro-3(2h)-pyridazinone hydrochloride trihydrate
11/07/2002	CA2448607A1 Colloidal metal compositions and methods
11/07/2002	CA2447748A1 Use of hiv-protease inhibitors to block cell migration and/or invasion, tissue infiltration and oedema formation
11/07/2002	CA2446514A1 Fused pyrimidines as antagonists of the corticotropin releasing factor (crf)
11/07/2002	CA2446497A1 Crf receptor antagonists
11/07/2002	CA2446083A1 Composition and methods for treatment of hyperplasia
11/07/2002	CA2446064A1 Nitrosated and nitrosylated nebivolol and its metabolites, compositions and methods of use
11/07/2002	CA2446052A1 Compositions and methods for treating vulvovaginitis and vaginosis
11/07/2002	CA2445967A1 Compositions comprising lopinavir and methods for enhancing the bioavailability of pharmaceutical agents
11/07/2002	CA2445963A1 Polymethoxylated flavones for treating insulin resistance
11/07/2002	CA2445871A1 Combinations of aldose reductase inhibitors and cyclooxygenase-2 inhibitors
11/07/2002	CA2445861A1 Pharmaceutically active uridine esters
11/07/2002	CA2445860A1 Pharmaceutical composition including ace/nep inhibitors and bioavailability enhancers
11/07/2002	CA2445859A1 Antidepressant azaheterocyclylmethyl derivatives of 7,8-dihydro-1,6,9-trioxa-3-aza-cyclopenta[a]naphthalene
11/07/2002	CA2445843A1 The use of enantiomeric pure escitalopram
11/07/2002	CA2445839A1 Anti-inflammatory 17.beta.-carbothioate ester derivatives of androstane with a cyclic ester group in position 17.alpha
11/07/2002	CA2445763A1 Compositions comprising an anti-microtubule agent and a polypeptide or a polysaccharide and the use thereof for the preparation of a medicament for the treatment of inflammatory conditions
11/07/2002	CA2445702A1 Control of compactability through crystallization
11/07/2002	CA2445697A1 Drug efflux pump inhibitor
11/07/2002	CA2445693A1 Compounds useful as intermediates for 4-aminoquinoline derivatives
11/07/2002	CA2445629A1 Substituted benzofurans and benzothiophenes, methods of making and methods of use as integrin antagonists
11/07/2002	CA2445623A1 Methods for preparing cetp inhibitors
11/07/2002	CA2445584A1 Injectable pamidronate disodium
11/07/2002	CA2445583A1 Antidepressant indoletetrahydropyridine derivatives of 2,3-dihydro-7h-[1,4]dioxino[2,3-e]indole
11/07/2002	CA2445581A1 Antidepressant azaheterocyclylmethyl derivatives of 2,3-dihydro-1,4-dioxino[2,3-f]quinoxaline
11/07/2002	CA2445568A1 Triazole-derived kinase inhibitors and uses thereof
11/07/2002	CA2445565A1 Compositions and methods of double-targeting virus infections and cancer cells
11/07/2002	CA2445552A1 Antidepressant (sssri) azaheterocyclymethyl derivatives of 7,8-dihydro-3h-t,9-dioxa-1,3-diazacyclopenta[a]naphthalene
11/07/2002	CA2445543A1 Antidepressant azaheterocyclylmethyl derivatives of oxaheterocycle-fused-¬1,4\|-benzodioxans
11/07/2002	CA2445528A1 Treatment of psychotic disorders comprising co-therapy with anticonvulsant derivatives and atypical antipsychotics
11/07/2002	CA2445524A1 Stent-based delivery of statins to prevent restenosis
11/07/2002	CA2445376A1 Substance rkb-3564 having angiogenesis inhibitory action
11/07/2002	CA2445373A1 Use of phyllanthus constituents for treating or preventing infections caused by hepatitis b viruses
11/07/2002	CA2445357A1 Pyrazole derived kinase inhibitors
11/07/2002	CA2445348A1 Novel benzylpiperidine compound
11/07/2002	CA2445343A1 Use of protein and essential amino acids to treat amenorrhea and related disorders
11/07/2002	CA2445330A1 Potassium channel opener
11/07/2002	CA2445314A1 Supplementary immunotherapeutics to be used after lung cancer removal
11/07/2002	CA2445294A1 Bisarylimidazolyl fatty acid amide hydrolase inhibitors
11/07/2002	CA2445290A1 A pharmaceutical tablet having a high api content
11/07/2002	CA2445262A1 Method for treating tumors by the administration of tegafur, uracil, folinic acid, and cyclophosphamide
11/07/2002	CA2444897A1 Sulfate of cephem compound
11/07/2002	CA2444882A1 Inhibitors of gsk-3 and crystal structures of gsk-3.beta. protein and protein complexes
11/07/2002	CA2444500A1 Triazole compounds useful in treating diseases associated with unwanted cytokine activity
11/07/2002	CA2444499A1 Triazole compounds useful in treating diseases associated with unwanted cytokine activity
11/07/2002	CA2444436A1 Dual inhibitors of pde 7 and pde 4
11/07/2002	CA2444429A1 Probucol monoesters and their use to increase plasma hdl cholesterol levels and improve hdl functionality
11/07/2002	CA2444334A1 Pharmaceutical combinations based on pyridoindolone derivatives and anticancer agents
11/07/2002	CA2443838A1 Use of mangafodipir for treating oxidative stress effects
11/07/2002	CA2443835A1 Fused heterocyclic inhibitors of phosphodiesterase (pde) 7
11/07/2002	CA2443625A1 Use of bisphosphonates in the treatment of bone metastasis associated with prostate cancer
11/07/2002	CA2443381A1 Use of azithromycin for the manufacture of a medicament for treatment of non-infective inflammatory diseases
11/07/2002	CA2442608A1 Crystalline hydrochloride salt of (2r)-anti-5-(3-[-4-(10,11-difluoromethanodibenzosuber-5-yl)piperazin-1-yl)-2-hydroxypoxy}quinoline
11/07/2002	CA2439943A1 Benzimidazoles that are useful in treating sexual dysfunction
11/07/2002	CA2438223A1 Carboxylic acid such as citric acid for desinfecting or enhacing the production of blood products such as plasma, cryoprecipitate or/and platelet
11/07/2002	CA2429001A1 Cysteine protease inhibitors
11/07/2002	CA2408369A1 Substituted indoles as parp inhibitors
11/06/2002	WO2001084962A2 Compositions containing folic acid and reduced folate
11/06/2002	EP1255112A2 Treatment of T-cell mediated diseases
11/06/2002	EP1254908A1 Preparation of a camptothecin derivative by intramolecular cyclisation
11/06/2002	EP1254907A1 Pyrrolopyridazine compound
11/06/2002	EP1254906A1 Tetrahydrothiopyran phenyloxazolidinone S,S-dioxides
11/06/2002	EP1254905A1 4-(2-Pyridyl)piperazines having 5HT7 receptor agonist activity
11/06/2002	EP1254904A1 Novel piperidine compounds and drugs containing the same
11/06/2002	EP1254903A1 4-Amino-2-(pyridin-2-yl)pyrimidine as microbicidal active substances
11/06/2002	EP1254902A1 Agents correcting gene expression regulatory error
11/06/2002	EP1254901A1 Nitrogen-containing 5-membered cyclic compounds and drugs containing these compounds as the active ingredient
11/06/2002	EP1254899A2 Piperazine derivatives and their use as anti-inflammatory agents
11/06/2002	EP1254895A1 Nitrogenous cyclic compounds and pharmaceutical compositions containing the same
11/06/2002	EP1254890A1 Derivatives of 3,3-diphenylpropylamines
11/06/2002	EP1254668A2 Combination of a serotonin reuptake inhibitor and a GABA-A alpha 2/3 agonist for use in anxiety and depression
11/06/2002	EP1254667A1 Drug comprising combination
11/06/2002	EP1254664A2 Enteral products containing indigestible oligosaccharides for treating and preventing otitis media in humans
11/06/2002	EP1254663A1 Anti-virus agent
11/06/2002	EP1254662A2 Methods and kits for treating depression or preventing deterioration of cognitive function
11/06/2002	EP1254661A1 Method for preventing dyskinesias with selective NMDA-Antagonists
11/06/2002	EP1254660A2 Methods, kits and compositions for using pyrrole derivatives against anxiety
11/06/2002	EP1254659A1 Stable emulsion compositions
11/06/2002	EP1254658A1 Remedies
11/06/2002	EP1254268A1 Methods and materials relating to leucine-rich repeat protein-like (lrr protein-like) polypeptides and polynucleotides
11/06/2002	EP1254265A1 Methods and materials relating to metallocarboxypeptidase-like polypeptides and polynucleotides
11/06/2002	EP1254259A1 Antisense modulation of pepck-cytosolic expression
11/06/2002	EP1254256A2 Novel nucleic acids and polypeptides
11/06/2002	EP1254253A1 Single stranded oligonucleotides, probes, primers and method for detecting spirochetes
11/06/2002	EP1254242A1 17 human secreted proteins
11/06/2002	EP1254239A2 Mammalian secreted group iii phospholipase a2
11/06/2002	EP1254238A2 Novel elongase gene and method for producing multiple-unsaturated fatty acids
11/06/2002	EP1254235A2 Drug metabolizing enzymes
11/06/2002	EP1254231A1 Genes encoding abc1 paralogs and the polypeptides derived therefrom
11/06/2002	EP1254222A1 Human gaba receptor proteins and polynucleotides encoding the same
11/06/2002	EP1254212A2 Methods of preparing and using a viral vector library
11/06/2002	EP1254209A2 Bioavailable composition of natural and synthetic hca
11/06/2002	EP1254176A2 Trade molecules and uses related thereto
11/06/2002	EP1254175A1 Human cystine knot polypeptide
11/06/2002	EP1254174A2 Human cyr61
11/06/2002	EP1254146A1 Processes for preparing clarithromycin polymorphs and novel polymorph iv
11/06/2002	EP1254145A1 N,o-amidomalonate platinum complexes
11/06/2002	EP1254140A1 Compounds of the saframycin-ecteinascidin series, uses, and synthesis thereof

1 ... 5658 5659 5660 5661 5662 5663 5664 5665 5666 5667 5668 5669 5670 5671 5672 5673 5674 5675 5676 5677 5678 ... 7860